January 10, 2003

LSR ANNOUNCES BOARD APPOINTMENTS

Princeton, New Jersey, January 10, 2003 – Life Sciences Research, Inc. ("LSR") (OTCBB: LSRI) announced today the appointment of two new members to its Board of Directors. Mr. Y. Sesay, an international businessman with an interest in the development of pharmaceutical products, and Mr. M. Faruque, Chairman of the Ghulam Faruque Group, have been elected to the Board, effective immediately.  Messrs. Sesay and Faruque will fill the Board seats made available by the retirements from the Board of Dr. John Caldwell and Mr. Kirby Cramer.

Andrew Baker, LSR’s Chairman, said “ Dr. Caldwell and Mr. Cramer have been long-standing friends of our Company, John having served as a director since 1996 and Kirby since 1998. We have greatly benefited from their advice and counsel and extend our thanks for their support during this important stage in the Company’s development”.

“As we begin our first full year as a US public company, we look forward to the able assistance of Messrs. Sesay and Faruque in LSR’s continuing progress.  The strategic changes our Board has overseen have made us a stronger Company and positioned us to move forward into this next stage in our development.  We look forward to working with our newly constituted Board to help guide us through the exciting future we see for Life Sciences Research.”

Life Sciences Research, Inc. is a global Contract Research Organization providing product development services to the pharmaceutical, agrochemical and biotechnology industries.  LSR brings leading technology and capability to support its clients in non-clinical safety testing of new compounds in early stage development and assessment.  The purpose of this work is to identify risks to humans, animals or the environment resulting from the use or manufacture of a wide range of chemicals which are essential components of LSR's clients' products.  The Company's services are designed to meet the regulatory requirements of governments around the world.  LSR operates research facilities in the United States (the Princeton Research Center, New Jersey) and the United Kingdom (Huntingdon and Eye, England).

This announcement contains statements that may be forward-looking as defined by the USA’s Private Securities Litigation Reform Act of 1995.  These statements are based largely on LSR’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond LSR’s control, as more fully described in LSR’s Registration Statement on Form S-1, dated July 12, 2002, and the Company’s Form 10-K for the fiscal year ended December 31, 2001, each as filed with the US Securities and Exchange Commission.